CNA Database

From Compendium of Cancer Genome Aberrations
Revision as of 14:28, 24 July 2016 by Snewman (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Disease Name MESH header Disease Id Prognosis Gene Name Band Cytogenetic Aberration Non-cytogenetic Characteristic Gene Entrez ID Cytoband Aberration Aberration Label Described Effect Bearing Therapy Type Therapy Name Therapy Class Therapy Id Diagnostic, Prognostic, Therapy related pubmed ids
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 MET 7q31.2 Amplification 4233 7q31.2 Gain MET Amplification Targeted Therapies May Be Available (i.e. Crizotinib) pos drug Crizotinib Therapy PMID 21716144 PMID 26628860
Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors D046152 KIT 4q12 Amplification 3815 4q12 Gain KIT Amplification Targeted Therapies May Be Available (i.e. Tyrosine Kinase Inhibitors); Recurring in Gastrointestinal Stromal Tumor; Imatinib Mylate Treatment pos drug Imatinib Mesylate Therapy 26098203
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 CRKL 22q11.21 Amplification 1399 22q11.21 Gain CRKL Amplification Associated With EGFR-TKI Resistance neg drug EGFR tyrosine kinase inhibitor Therapy 24939008, 22586683
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 MET 7q31.2 Amplification 4233 7q31.2 Gain MET Amplification Acquired Resistance To EGFR Inhibitors In EGFR-Mutant Tumors neg drug EGFR inhibitors Therapy 24348666, 26628860
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 FGFR1 8p11.22 Amplification 2260 8p11.22 Gain FGFR1 Amplification Inhibited By Ponatinib Treatment pos drug Ponatinib Therapy 23563700
Squamous Cell Lung Cancer Lung Neoplasms D008175 MYC 8q24.21 Overexpression 4609 8q24.21 Gain MYC overexpression Benefit From FGFR Inhibitor Therapy With Concomitant FGFR1 Amplification pos drug FGFR inhibitor Therapy 24302556
Squamous Cell Lung Cancer Lung Neoplasms D008175 FGFR1 8p11.22 8p11.22 Amplification Amplification 2260 8p11.22 Gain FGFR1 Amplification Benefit From FGFR Inhibitor Therapy With Concomitant MYC Overexpression pos drug FGFR inhibitor Therapy 24302556
Ovarian Ovarian Neoplasms D010051 CCNE1 19q12 Amplification 898 19q12 Gain CCNE1 Amplification Targeted Therapies May Be Available (i.e. CDK2 Inhibitors) pos CDK2 inhibitor Therapy 23289505, 26204491, 25633797, 25892415
Ovarian Ovarian Neoplasms D010051 ERBB2 17q12 Amplification 2064 17q12 Gain HER2 Amplification Targeted Therapies May Be Available (i.e. HER2 Inhibitors) pos HER2 inhibitor Therapy 25674538
Ovarian Ovarian Neoplasms D010051 KRAS 12p12.1 Amplification 3845 12p12.1 Gain KRAS Amplification Targeted Therapies May Be Available (i.e. RAS Inhibitors) pos RAS inhibitor Therapy 23289505, 26691679
Ovarian Ovarian Neoplasms D010051 BRCA1 17q21.31 Deletion 672 17q21.31 Loss BRCA1 Deletion Targeted Therapies May Be Available (i.e.PARP Inhibitors) pos PARP inhibitors Therapy 24225019, 26483957
Ovarian Ovarian Neoplasms D010051 BRCA2 13q13.1 Deletion 675 13q13.1 Loss BRCA2 Deletion Targeted Therapies May Be Available (i.e. PARP Inhibitors) pos PARP inhibitors Therapy 24225019, 26483957
Ovarian Ovarian Neoplasms D010051 PTEN 10q23.31 Bi-allelic deletion 5728 10q23.31 Loss PTEN Bi-allelic deletion Targeted Therapies May Be Available (i.e. PI3K Pathway Inhibitors) pos PI3K pathway inhibitors Therapy 24387334, 23289505, 25533673
Myelodysplastic Syndrome Myelodysplastic Syndromes D009190 5q deletion 5q Loss 5q deletion Targeted Therapies May Be Available (i.e. Lenalidomide) pos drug Lenalidomide Therapy 22488943
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 1p36.13 amplification 1p36.13 Gain 1p36.13 amplification Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 1p42.3 amplification 1p42.3 Gain 1p42.3 amplification Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 3p21.31 amplification 3p21.31 Gain 3p21.31 amplification Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 7q11.23 amplification 7q11.23 Gain 7q11.23 amplification Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 16p13.3 amplification 16p13.3 Gain 16p13.3 amplification Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 9p21.3 loss 9p21.3 Loss 9p21.3 loss Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 14q11.2 loss 14q11.2 loss Loss 14q11.2 loss Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 CDKN2A 9p21.3 Loss 1029 9p21.3 Loss CDKN2A/B Loss Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 CDKN2B 9p21.3 Loss 1030 9p21.3 Loss CDKN2A/B Loss Associated With Chemoresistance neg chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 1p36.11 gain 1p36.11 Gain 1p36.11 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 1p36.22 gain 1p36.22 Gain 1p36.22 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 2q11.2 gain 2q11.2 Gain 2q11.2 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 8q24.3 gain 8q24.3 Gain 8q24.3 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 12p13.33 gain 12p13.33 Gain 12p13.33 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 22q13.2 gain 22q13.2 Gain 22q13.2 gain Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse D016403 6p21.32 loss 6p21.32 Loss 6p21.32 loss Associated With Chemo-Sensitive pos chemotherapy Chemotherapy Therapy 21504712
Mantle Cell Lymphoma Lymphoma, Mantle-Cell D020522 MDM2 12q15 Amplification 4193 12q15 Gain MDM2 Amplification Target For Nutlin-3 Therapy (MDM2 Antagonist; Activate TP53) pos drug Nutlin-3 Therapy 23303139, 25439588, 25201201
Breast Cancer Breast Neoplasms D001943 ERBB2 17q12 Amplification Increased expression 2064 17q12 Gain ERBB2 Amplification Targeted Therapies May Be Available (i.e. ERBB2 Inhibitor (HER2)) pos drug ERBB2 inhibitor (HER2) Therapy 24470511, 24921704, 25674538, 26557900, 26635612
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 KIT 4q12 Amplification Increased expression 3815 4q12 Gain KIT Amplification Targeted Therapies May Be Available (i.e. KIT Inhibitor) pos drug KIT inhibitor Therapy 24190702
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 PDGFRB 5q32 Amplification Increased expression 5159 5q32 Gain PDGFRB Amplification Targeted Therapies May Be Available (i.e. PDGFRB Inhibitor) pos drug PDGFRB inhibitor Therapy 24359404, 24872713
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 FLT1 13q12.3 Amplification Increased expression 13q12.3 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) pos drug VEGFR 1/2/3 inhibitor Therapy 24243495, 25482937, 25773809
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 KDR 4q12 Amplification Increased expression 4q12 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) pos drug VEGFR 1/2/3 inhibitor Therapy 24243495, 26309897
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 FLT4 5q35.3 Amplification Increased expression 5q35.3 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) pos drug VEGFR 1/2/3 inhibitor Therapy 24243495
Colorectal Cancer Colorectal Neoplasms D015179 VEGFA 6p21.1 Amplification Increased expression 6p21.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24355210
Colorectal Cancer Colorectal Neoplasms D015179 VEGFB 11q13.1 Amplification Increased expression 11q13.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24355210
Glioblastoma Glioblastoma D005909 VEGFA 6p21.1 Amplification Increased expression 6p21.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24076268
Glioblastoma Glioblastoma D005909 VEGFB 11q13.1 Amplification Increased expression 11q13.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24076268
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 VEGFA 6p21.1 Amplification Increased expression 6p21.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24076268
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 VEGFB 11q13.1 Amplification Increased expression 11q13.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24076268
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 VEGFA 6p21.1 Amplification Increased expression 6p21.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24243495
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 VEGFB 11q13.1 Amplification Increased expression 11q13.1 Gain VEGF Amplification Targeted Therapies May Be Available (i.e. VEGF Inhibitor) pos drug VEGF inhibitor Therapy 24243495
Medullary Thyroid Cancer Thyroid Neoplasms D013964 FLT3 13q12.2 Amplification Increased expression 2322 13q12.2 Gain FLT3 Amplification Targeted Therapies May Be Available (i.e. FLT3 Inhibitor) pos drug FLT3 inhibitor Therapy 24756790, 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 KIT 4q12 Amplification Increased expression 3815 4q12 Gain KIT Amplification Targeted Therapies May Be Available (i.e. KIT Inhibitor) pos drug KIT inhibitor Therapy 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 MET 7q31.2 Amplification Increased expression 4233 7q31.2 Gain MET Amplification Targeted Therapies May Be Available (i.e. MET Inhibitor) pos drug MET inhibitor Therapy 24266843, 26628860, 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 RET 10q11.21 Amplification Increased expression 5979 10q11.21 Gain RET Amplification Targeted Therapies May Be Available (i.e. RET Inhibitor) pos drug RET inhibitor Therapy 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 FLT1 13q12.3 Amplification Increased expression 13q12.3 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) pos drug VEGFR inhibitor Therapy 25482937, 25773809, 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 KDR 4q12 Amplification Increased expression 4q12 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) pos drug VEGFR inhibitor Therapy 25773809, 26635725
Medullary Thyroid Cancer Thyroid Neoplasms D013964 FLT4 5q35.3 Amplification Increased expression 5q35.3 Gain VEGFR Amplification Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) pos drug VEGFR inhibitor Therapy 26635725
Colorectal Cancer Colorectal Neoplasms D015179 EGFR 7p11.2 Amplification Increased expression 1956 7p11.2 Gain EGFR Amplification Targeted Therapies May Be Available (i.e. EGFR Inhibitor) pos drug EGFR inhibitor Therapy 24472471, 25110867
Squamous Cell Cancer Of Head And Neck Head and Neck Neoplasms D006258 EGFR 7p11.2 Amplification Increased expression 1956 7p11.2 Gain EGFR Amplification Targeted Therapies May Be Available (i.e. EGFR Inhibitor) pos drug EGFR inhibitor Therapy 24412287, 25110867
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 ALK 2p23.1 Amplification Increased expression 238 2p23.1 Gain ALK Amplification Targeted Therapies May Be Available (i.e. ALK Inhibitor) pos drug ALK inhibitor Therapy 26468446, 25806340
Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung D002289 MET 7q31.2 Amplification Increased expression 4233 7q31.2 Gain MET Amplification Targeted Therapies May Be Available (i.e. MET Inhibitor) pos drug MET inhibitor Therapy 24355409, 25992382
Pancreatic Cancer Pancreatic Neoplasms D010190 EGFR 7p11.2 Amplification Increased expression 1956 7p11.2 Gain EGFR Amplification Targeted Therapies May Be Available (i.e. EGFR Inhibitor) pos drug EGFR inhibitor Therapy 24432033, 25110867
Pancreatic Neuroendocrine Tumor Pancreatic Neoplasms D010190 MTOR 1p36.22 Amplification Increased expression 2475 1p36.22 Gain mTOR Amplification Targeted Therapies May Be Available (i.e. mTOR Inhibitor) pos drug mTOR inhibitor Therapy 24333502
Renal Cell Carcinoma Carcinoma, Renal Cell D002292 MTOR 1p36.22 Amplification Increased expression 2475 1p36.22 Gain mTOR Amplification Targeted Therapies May Be Available (i.e. mTOR Inhibitor) pos drug mTOR inhibitor Therapy 26309897, 24333502
Gastrointestinal Stromal Tumors Gastrointestinal Stromal Tumors D046152 KIT 4q12 Amplification Increased expression 3815 4q12 Gain KIT Amplification Targeted Therapies May Be Available (i.e. KIT Inhibitor) pos drug KIT inhibitor Therapy 24384849
Dermatofibrosarcoma Protuberans Dermatofibrosarcoma D018223 PDGFRA 4q12 Amplification Increased expression 4q12 Gain PDGFR Amplification Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) pos drug PDGFR inhibitor Therapy 24359404, 24872713
Dermatofibrosarcoma Protuberans Dermatofibrosarcoma D018223 PDGFRB 5q32 Amplification Increased expression 5q32 Gain PDGFR Amplification Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) pos drug PDGFR inhibitor Therapy 24359404, 24872713
Retrieved from "https://ccga.io/index.php?title=CNA_Database&oldid=1069"